"10.1371_journal.pone.0090479","plos one","2014-03-07T00:00:00Z","Jenny Link; Malin Lundkvist Ryner; Katharina Fink; Christina Hermanrud; Izaura Lima; Boel Brynedal; Ingrid Kockum; Jan Hillert; Anna Fogdell-Hahn","Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden","Conceived and designed the experiments: AFH JH MLR JL KF IK BB. Performed the experiments: MLR CH. Analyzed the data: JL IL. Contributed reagents/materials/analysis tools: JL MLR KF IL IK JH AFH. Wrote the paper: MLR. Provided treatment data: KF. Revised the manuscript: JL MLR KF CH IL BB IK JH AFH.","Malin Lundkvist Ryner has read the journal's policy and has the following conflicts: JL has received research support from the Swedish Association for Persons with Neurological Disabilities. She has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° [115303], resources of which are composed of financial contribution from the European Union's Seventh Framework Program (FP7/2007-2013) and EFPIA companies' in kind contribution. MLR has received research support from BiogenIdec, Sanofi-Aventis and the Swedish Association for Persons with Neurological Disabilities, as well as received honoraria for lectures by BiogenIdec. KF has received travel compensation for consultancy work from Novartis and Teva. CH, IL and BB report no conflicts of interest. IK has received research grants from Association for Persons with Neurological Disabilities. JH received honoraria for serving on advisory boards for BiogenIdec, Merck-Serono and Novartis and for speaker's fees from BiogenIdec, Merck-Serono, Bayer-Schering, Teva and Sanofi-Aventis. He has served as P.I. for and received projects supported by BiogenIdec, Merck-Serono, and Bayer-Schering. His MS research is funded by the Swedish Research Council, Bibbi and Nils Jensens Foundation and the European Commission. AFH has received research grants from Association for Persons with Neurological Disabilities and received unrestricted research grants from Merck-Serono, BiogenIdec; served as consultant for Johnson & Johnson; received honoraria for lectures by BiogenIdec and Sanofi-Aventis. She has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° [115303], resources of which are composed of financial contribution from the European Union's Seventh Framework Program (FP7/2007-2013) and EFPIA companies' in kind contribution. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2014","03","Jenny Link","JL",9,TRUE,7,2,2,1,TRUE,TRUE,FALSE,0,NA,FALSE
